The SPORE Career Development Program (CDP) prepares physicians and scientists for independent careers as investigators in translational research in prostate cancer. We have designed the CDP to form both an interdepartmental and an interinstitutional training ground to produce investigators who will become intellectual leaders in their fields of interest. By combining the research and academic resources available throughout Memorial Sloan-Kettering Cancer Center and at our affiliated institutions, we have a long tradition of successful fellowship training and faculty development for both internally and externally trained candidates. Recruiting and/or developing the career of new faculty members committed to translational research in prostate cancer is a centerpiece of our program, but in previous SPORE cycles we were equally focused on training and supporting senior research fellows who were committed to a career in translational research in prostate cancer. In accordance with changes to the current SPORE guidelines, we have reworked the specific aims of our Career Development Program. Our plan is to use the SPORE career development funds, supplemented with an equal amount of institutional funds, over the next 5 years to continue to recruit and develop the careers of junior faculty members and experienced investigators?from both basic research and clinical backgrounds?committed to translational research in prostate cancer.
Aim 1 : To recruit and/or develop the career of 1 or 2 junior faculty members or established investigators each year who are committed to translational research in prostate cancer Aim 2: To provide the scholarly basis for effective translational research in prostate cancer through a broad educational program in prostate cancer, emphasizing the knowledge base for conducting translational research through academic courses, scheduled conferences, and a program of invited speakers and visiting professors
concern, prostate cancer is the second deadliest cancer in men. The CDP plays a key role in recruiting and training exceptional scientific talent for translational research projects in prostate cancer.
|Cheal, Sarah M; Punzalan, Blesida; Doran, Michael G et al. (2014) Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcino Eur J Nucl Med Mol Imaging 41:985-94|
|Bancroft, Elizabeth K; Page, Elizabeth C; Castro, Elena et al. (2014) Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol 66:489-99|
|Sjoberg, Daniel D (2014) Toward a Smarter Prostate Cancer Screening Program. Eur Urol :|
|Ehdaie, Behfar; Vertosick, Emily; Spaliviero, Massimiliano et al. (2014) The impact of repeat biopsies on infectious complications in men with prostate cancer on active surveillance. J Urol 191:660-4|
|Ahmad-Tajudin, Asilah; Adler, Belinda; Ekstrom, Simon et al. (2014) MALDI-target integrated platform for affinity-captured protein digestion. Anal Chim Acta 807:1-8|
|Vickers, Andrew J (2014) Clinical trials in crisis: Four simple methodologic fixes. Clin Trials 11:615-21|
|Bryant, Richard J; Lilja, Hans (2014) Emerging PSA-based tests to improve screening. Urol Clin North Am 41:267-76|
|Vertosick, Emily A; Poon, Bing Ying; Vickers, Andrew J (2014) Relative value of race, family history and prostate specific antigen as indications for early initiation of prostate cancer screening. J Urol 192:724-8|
|Vickers, Andrew J; Pepe, Margaret (2014) Does the net reclassification improvement help us evaluate models and markers? Ann Intern Med 160:136-7|
|Shi, Yuji; Wang, Junru; Chandarlapaty, Sarat et al. (2014) PTEN is a protein tyrosine phosphatase for IRS1. Nat Struct Mol Biol 21:522-7|
Showing the most recent 10 out of 310 publications